Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB: Functional Analysis of BRCAness
2018-001660-29Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib in epithelial ovarian cancer (EOC) (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Objective response rate. Started Oct 2018; status: active.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2018-001660-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001660-29.